When the CD133+ GBM cells were treated with shRNA targeting NANOG or OCT4 in combination with TMZ, the level of cell death was significantly higher compared to with the TMZ treatment alone, suggesting that the inhibition of NANOG or OCT4 increased the efficacy of TMZ. The gene discussed is POU5F1; the disease is glioblastoma.